

Passing of Professor Allan Cripps AO, Non-Executive Director

Neurotech International Limited (ASX: NTI) ("Neurotech" or "the Company"), a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders, today is very saddened to announce the passing of Professor Allan Cripps AO, Non-Executive Director and Chief Scientist of the Company.

Mr Mark Davies, Chairman of Neurotech said, "On behalf of the Board of Directors and staff of Neurotech International, we are deeply saddened to announce the passing of Emeritus Professor Cripps who has dedicated exceptional service to the Company since his appointment as a Director. Allan was a distinguished academic, clinical scientist and health services leader with over 20 years' experience in the health and pharmaceutical industries having made an extraordinary contribution to the industry over that time. Since May 2021, Allan has been instrumental in helping to shape Neurotech's pre-clinical and clinical programs, which has added significant value to the Company and we all express our sincerely condolences to his family and colleagues during this difficult time."

Vale Professor Allan Cripps AO.

Authority

This announcement has been authorised for release by the Board of Neurotech International Limited.

Investors:

Dr Thomas Duthy
Executive Director
td@neurotechinternational.com
+61 (0)402 493 727

About Neurotech

Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders. Neurotech has completed a Phase I/II clinical trial in Autism Spectrum Disorder (ASD), which demonstrated excellent safety and efficacy results at 28 days and 20 weeks of treatment with NTI164. The Company will commence a Phase II/III randomised, double-blind, placebo-controlled clinical trial in ASD in Q4 CY2022. Neurotech plans to conduct additional Phase I/II trials in Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS, along with cerebral palsy during CY2023. Neurotech is also commercialising Mente, the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity.

For more information about Neurotech please visit <http://www.neurotechinternational.com>.